全文获取类型
收费全文 | 5694篇 |
免费 | 354篇 |
国内免费 | 45篇 |
专业分类
耳鼻咽喉 | 48篇 |
儿科学 | 149篇 |
妇产科学 | 139篇 |
基础医学 | 960篇 |
口腔科学 | 109篇 |
临床医学 | 560篇 |
内科学 | 1149篇 |
皮肤病学 | 162篇 |
神经病学 | 601篇 |
特种医学 | 177篇 |
外科学 | 569篇 |
综合类 | 47篇 |
一般理论 | 6篇 |
预防医学 | 390篇 |
眼科学 | 126篇 |
药学 | 452篇 |
中国医学 | 46篇 |
肿瘤学 | 403篇 |
出版年
2023年 | 44篇 |
2022年 | 139篇 |
2021年 | 307篇 |
2020年 | 147篇 |
2019年 | 204篇 |
2018年 | 176篇 |
2017年 | 125篇 |
2016年 | 172篇 |
2015年 | 183篇 |
2014年 | 254篇 |
2013年 | 312篇 |
2012年 | 512篇 |
2011年 | 575篇 |
2010年 | 321篇 |
2009年 | 227篇 |
2008年 | 409篇 |
2007年 | 378篇 |
2006年 | 334篇 |
2005年 | 300篇 |
2004年 | 256篇 |
2003年 | 220篇 |
2002年 | 208篇 |
2001年 | 37篇 |
2000年 | 23篇 |
1999年 | 39篇 |
1998年 | 32篇 |
1997年 | 23篇 |
1996年 | 11篇 |
1995年 | 13篇 |
1994年 | 14篇 |
1993年 | 6篇 |
1992年 | 5篇 |
1991年 | 5篇 |
1990年 | 5篇 |
1988年 | 3篇 |
1987年 | 3篇 |
1986年 | 4篇 |
1985年 | 3篇 |
1984年 | 5篇 |
1983年 | 4篇 |
1982年 | 4篇 |
1981年 | 5篇 |
1980年 | 5篇 |
1979年 | 5篇 |
1978年 | 6篇 |
1977年 | 3篇 |
1975年 | 4篇 |
1974年 | 5篇 |
1971年 | 3篇 |
1934年 | 2篇 |
排序方式: 共有6093条查询结果,搜索用时 15 毫秒
1.
Bielik Peter Bonczek Ondřej Krejčí Přemysl Zeman Tomáš Izakovičová-Hollá Lydie Šoukalová Jana Vaněk Jiří Vojtěšek Bořivoj Lochman Jan Balcar Vladimir J. Šerý Omar 《Clinical oral investigations》2022,26(12):7045-7055
Clinical Oral Investigations - The aim of this study was the analysis of WNT10A variants in seven families of probands with various forms of tooth agenesis and self-reported family history of... 相似文献
2.
Emile Gogineni Zaker Rana Michael Wotman Jessie Karten Adam Riegel Mihaela Marrero Luis Maduro Dev Kamdar Douglas Frank Doru Paul Nagashree Seetharamu Maged Ghaly 《Journal of Geriatric Oncology》2021,12(1):122-127
PurposeManagement of head and neck cancers (HNC) in older adults is a common but challenging clinical scenario. We assess the impact of Stereotactic Body Radiation Therapy (SBRT) on survival utilizing the Geriatric-8 (G8) questionnaire.Materials and methods171 HNC patients, deemed medically unfit for definitive treatment, were treated with SBRT ± systemic therapy. G8 questionnaires were collected at baseline, at 4–6 weeks, and at 2–3 months post-treatment. Patients were stratified according to their baseline G8 score: <11 as ‘vulnerable’, 11–14 as ‘intermediate’, and >14 as ‘fit’. Overall survival (OS) was assessed through univariate Kaplan Meier analysis. Repeated measures ANOVA was used to determine if baseline characteristics affected G8 score changes.ResultsMedian follow-up was seventeen months. 60% of patients presented with recurrent HNC, 30% with untreated HNC primaries, and 10% with metastatic non-HNC primaries. Median age was 75 years. Median Charlson Comorbidity Index score was 2. 51% of patients were ‘vulnerable’, 37% were ‘intermediate’, and 12% were ‘fit' at baseline, with median survival of 13.2, 24.3, and 41.0 months, respectively (p = .004). Patients who saw a decrease in their follow-up G8 score (n = 69) had significantly lower survival than patients who had stable or increased follow-up G8 scores (n = 102), with median survival of 8.6 vs 36.0 months (p < .001).ConclusionThe G8 questionnaire may be a useful tool in upfront treatment decision-making to predict prognosis and prevent older patients from receiving inappropriate anti-cancer treatment. Decline in follow-up G8 scores may also predict worse survival and aid in goals of care following treatment. 相似文献
3.
4.
5.
6.
Adherence to continuous positive airway pressure treatment in patients with Alzheimer's disease and obstructive sleep apnea. 总被引:2,自引:0,他引:2
Liat Ayalon Sonia Ancoli-Israel Carl Stepnowsky Matthew Marler Barton W Palmer Lianqi Liu Jose S Loredo Jody Corey-Bloom Deborah Greenfield Jana Cooke 《The American journal of geriatric psychiatry》2006,14(2):176-180
OBJECTIVE: This analysis examined whether patients with Alzheimer disease (AD) tolerate continuous positive airway pressure (CPAP). METHOD: Thirty patients with AD were randomized to CPAP or sham CPAP and completed sleep, depression, and quality-of-life questionnaires. Participants could choose to continue treatment after the trial. RESULTS: Patients wore CPAP for 4.8 hours per night. More depressive symptoms were associated with worse adherence (rS=-0.37; N=30, p<0.04). Patients who continued using CPAP had fewer depressive symptoms (t [19]=2.45, p=0.02) and better adherence (t [19]=2.32, p=0.03) during the trial. CONCLUSION: Patients with AD with obstructive sleep apnea can tolerate CPAP. Adherence and long-term use may be more difficult among those patients with more depressive symptoms. 相似文献
7.
Blanka Ríhová Jirí Strohalm Jana Prausová Katerina Kubácková Markéta Jelínková Lad'ka Rozprimová Milada Sírová Dana Plocová Tomás Etrych Vladimír Subr Tomás Mrkvan Marek Kovár Karel Ulbrich 《Journal of controlled release》2003,91(1-2):1-16
An N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer carrier containing doxorubicin and human immunoglobulin as an actively/passively targeting moiety was used in four patients with generalized breast cancer resistant to standard cytotoxic chemotherapy. The dose and time schedule were deduced from a Phase I clinical trial in which doxorubicin bound to HPMA copolymer carrier (PK1) was tested. It was confirmed that the Dox-HPMA-HuIg conjugate is stable and doxorubicin remains in the peripheral blood with a small amount also in the urine, mostly in its polymer-bound form. More than 116 biochemical, immunological and hematological parameters were determined for blood samples taken from patients 24 h, 48 h, 72 h and 1 to 11 weeks after treatment. Depending on the patient, some parameters decreased permanently or temporarily to the normal level (CRP, C3, CA 72-4, beta(2)-microglobulin, ferritin, CEA, CA 125, CD4, CD8, CE19, CD16(+)56(+), leu, ery) and some moved markedly towards physiological values (AST, ALT, ALP, GMT, CA 15-3, NSE, AFP). While the number of peripheral blood reticulocytes was significantly decreased after treatment with the classical free drug, their number was not affected or was even elevated after treatment with Dox-HPMA-HuIg. Increased absolute numbers of CD16(+)56(+) and CD4(+) cells in the peripheral blood and activation of NK and LAK cells in all patients support data obtained in experimental animals, pointing to a dual, i.e. cytostatic and immunomobilizing character of Dox-HPMA conjugates containing a targeting immunoglobulin moiety. 相似文献
8.
Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. 总被引:4,自引:0,他引:4
Renzo Cescato Stefan Schulz Beatrice Waser Véronique Eltschinger Jean E Rivier Hans-Jürgen Wester Michael Culler Mihaela Ginj Qisheng Liu Agnes Schonbrunn Jean Claude Reubi 《Journal of nuclear medicine》2006,47(3):502-511
The uptake of radiolabeled somatostatin analogs by tumor cells through receptor-mediated internalization is a critical process for the in vivo targeting of tumoral somatostatin receptors. In the present study, the somatostatin receptor internalization induced by a variety of somatostatin analogs was measured with new immunocytochemical methods that allow characterization of trafficking of the somatostatin receptor subtype 2 (sst2), somatostatin receptor subtype 3 (sst3), and somatostatin receptor subtype 5 (sst5) in vitro at the protein level. METHODS: Human embryonic kidney 293 (HEK293) cells expressing the sst2, sst3, or the sst5 were used in a morphologic immunocytochemical internalization assay using specific sst2, sst3 and sst5 antibodies to qualitatively and quantitatively determine the capability of somatostatin agonists or antagonists to induce somatostatin receptor internalization. In addition, the internalization properties of a selection of these agonists have been compared and quantified in sst2-expressing CHO-K1 cells using an ELISA. RESULTS: Agonists with a high sst2-binding affinity were able to induce sst2 internalization in the HEK293 and CHO-K1 cell lines. New sst2 agonists, such as Y-DOTA-TATE, Y-DOTA-NOC, Lu-DOTA-BOC-ATE (where DOTA is 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; TATE is [Tyr3, Thr8]-octreotide; NOC is [1-NaI3]-octreotide; and BOC-ATE is [BzThi3, Thr8]-octreotide), iodinated sugar-containing octreotide analogs, or BIM-23244 were considerably more potent in internalizing sst2 than was DTPA-octreotide (where DTPA is diethylenetriaminepentaacetic acid). Similarly, compounds with high sst3 affinity such as KE108 were able to induce sst3 internalization. In sst2- or sst3-expressing cell lines, agonist-induced receptor internalization was efficiently abolished by sst2- or sst3-selective antagonists, respectively. Antagonists alone had no effect on sst2 or sst3 internalization. We also showed that somatostatin-28 and somatostatin-14 can induce sst5 internalization. Unexpectedly, however, potent sst5 agonists such as KE108, BIM-23244, and L-817,818 were not able to induce sst5 internalization under the same conditions. CONCLUSION: Using sensitive and reproducible immunocytochemical methods, the ability of various somatostatin analogs to induce sst2, sst3, and sst5 internalization has been qualitatively and quantitatively determined. Whereas all agonists triggered sst2 and sst3 internalization, sst5 internalization was induced by natural somatostatin peptides but not by synthetic high-affinity sst5 agonists. Such assays will be of considerable help for the future characterization of ligands foreseen for nuclear medicine applications. 相似文献
9.
Libor Velíek† Jana Velíková Yael Ptachewich Shlomo Shinnar‡ Solomon L. Mosh醇 《Epilepsia》1995,36(2):179-185
Summary We determined the effects of the N-methyl-Daspartate (NMDA) receptor blocker MK-801 (0.05, 0.1, and 0.5 mg/kg intraperitoneally, i.p.) and phenytoin (PHT, 5, 10, and 20 mg/kg i.p.) on flurothyl-induced clonic and tonic-clonic seizures in 9-, 1 5, 30-, and 60-day-old male rats. Both agents had seizure-, age-, and dose-specific effects. The highest dose of MK-801 was anticonvulsant against clonic flurothyl-induced seizures only in 9- and 60-day-old rats, but suppressed tonic-clonic seizures in all ages. The lowest dose of MK-801 (0.05 mg/kg) produced significant anticonvulsant effects only in 15 day old rats. PHT did not have any effect on clonic seizures throughout development. Both doses of PHT (10 and 20 mg/kg) were anticonvulsant against tonic-clonic seizures in adult rats but not in any other age group. The results indicate that NMDA receptors play an important role in tonic-clonic flurothyl-induced seizures throughout development (especially in 15-day-old rats) and that the anticonvulsant effects of PHT may vary at different stages of brain development. 相似文献
10.
Age-Specific Effects of Baclofen on Pentylenetetrazol-Induced Seizures in Developing Rats 总被引:1,自引:0,他引:1
Summary: Purpose : To determine whether seizures have age-specific features, we studied the role of γ-aminobutyric acid, (GABAB) transmission in rats of various ages (9, 15, 30, and 60 postnatal days). Methods: We used a GABA, receptor agonist baclofen (2 or 5 mg/kg intraperitoneally, i.p.) and a GABAB receptor antagonist CGP 35348 (100 or 600 mg/kg i.p.) in the pentylenetetrazol (PTZ)-induced model of clonic and tonic-clonic seizures (100 mg/kg subcutaneously, s.c.).
Results : Whereas baclofen was anticonvulsant and CGP 35348 proconvulsant in most animals, there were distinct age-related differences in the effectiveness of these drugs and the antagonist had some anticonvulsant activity in adults. Furthermore, the two drugs acting at GABAB receptors had a different profile of action in clonic seizures as compared with tonic-clonic seizures.
Conclusions : The differences in the age-specific action of the GABAB agonist and antagonist suggest that different GABAB receptor subsets may mediate the drug effects. The results indicate that putative antiepileptic drugs (AEDs) must be tested during development because it may not be possible to extrapolate age-specific anticonvulsant effects from studies in adult animals. 相似文献
Results : Whereas baclofen was anticonvulsant and CGP 35348 proconvulsant in most animals, there were distinct age-related differences in the effectiveness of these drugs and the antagonist had some anticonvulsant activity in adults. Furthermore, the two drugs acting at GABA
Conclusions : The differences in the age-specific action of the GABA